Immunovant, Inc.
Financial highlights
| Metric | FY March 31, 2026 | FY March 31, 2025 | FY March 31, 2024 | FY March 31, 2023 | FY March 31, 2022 |
|---|---|---|---|---|---|
| Operating expenses | $532.9M | $438.2M | $282.7M | $218.3M | $156.0M |
| Cash from operations | -$407.3M | -$375.9M | -$214.2M | -$188.2M | -$106.1M |
| Capital expenditure | $8,000 | $759,000 | $360,000 | $197,000 | $254,000 |
| Free cash flow | -$407.3M | -$376.6M | -$214.6M | -$188.4M | -$106.4M |
| Total assets | $957.0M | $776.2M | $666.4M | $405.8M | $515.6M |
| Total liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $45.7M |
Shares outstanding 203.5M · Free float 96.3%
Annual filing data through FY ended March 31, 2026; float as of July 4, 2026.